<DOC>
	<DOC>NCT00976495</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of dapagliflozin on kidney function, as assessed by glomerular filtration rate.</brief_summary>
	<brief_title>Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Type 2 diabetes and inadequate glycemic control, defined as A1C ≥ 6.6 and ≤ 9.5% Stable dose of metformin AND/OR a sulfonylurea, for at least 4 weeks prior to the enrollment visit Inadequate blood pressure (BP) control, defined as systolic BP (SBP) ≥ 130 and &lt; 165 mmHg, AND/OR diastolic BP (DBP) ≥ 80 and &lt; 105 mmHg Cpeptide ≥ 0.8 ng/mL Estimated GFR by the Modification of Diet in Renal Disease (MDRD) formula &gt; 60 mL/min/1.73m² and &lt; 150 mL/min/1.73m² Urine albumin:creatinine ratio (UACR) &lt; 300 mg/g BMI ≤ 45.0 kg/m2 Administration of diuretics or other medication approved for the treatment of hypertension (with the exception of either ACEI or ARB), at any dose during the 12 weeks prior to the enrollment visit History of adverse reaction to radiocontrast dye Allergy or contraindication to use of thiazide diuretics Aspartate Aminotransferase (AST) &gt; 3X Upper limit of normal (ULN) Alanine aminotransferase (ALT) &gt; 3X ULN Serum Total Bilirubin &gt; 1.5X ULN Serum Creatinine (Scr) ≥ 1.50 mg/dL (133 μmol/l) for men; SCr ≥ 1.40 mg/dL (124 μmol/l) for women Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncologic, endocrine, psychiatric, or rheumatic diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>